Petasites hybridus in migraine prophylaxis: literature review

Authors

Keywords:

Petasites hybridus, Butterbur, Migraine, Prophylactic treatment

Abstract

Introduction
Over the past 25 years, Petasites hybridus has been used effectively in migraine prophylaxis. It acts on its pathophysiological mechanisms, modulating nociception, reducing the release of CGRP, decreasing inflammatory mediators and blocking calcium channels.
Objective
To review clinical studies already published on Petasites hybridus in migraine prophylaxis, with emphasis on the initial study by Grossmann and Schmidramsl in 2000.
Methods
This study was an integrative and retrospective review of articles on the use of Petasites hybridus in the prophylactic treatment of migraine that were published in English in the last 25 years.
Results
Five clinical studies were found, all placebo-controlled, three of which were double-blind, involving 488 patients with migraine aged between 6 and 60 years. These studies showed that Petasites hybridus was superior to placebo, proving its effectiveness in the prophylactic treatment of migraine and with good tolerability, including by children and adolescents.
Conclusions
Clinical studies proved that Petasites hybridus was well tolerated by children and adults and effective in migraine prophylaxis, reducing the number of days with headache by ≥ 50% in the first three months.

Downloads

Download data is not yet available.

References

Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, ... and Zukerman E. A nationwide population-based study of migraine in Brazil. Cephalalgia. 2009;29(6):642-9 Doi:10.1111/j.1468-2982.2008.01782.x.

Steiner TJ, Stovner LJ, Vos T, Jensen R and Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17 Doi.10.1186/s10194-018-0846-2.

Bussone G. Pathophysiology of migraine. Neurol Sci. 2004;25(suppl 3):239-41 Doi.10.1007/s10072-004-0295-3.

Recober A. Pathophysiology of migraine. Continuum (Minneap Minn). 2021;27(3):586-96 Doi.10.1212/CON.0000000000000983.

Krymchantowski AV. Condutas em Cefaleia: Avaliação e Tratamento. São Paulo: Lippincott Williams & Wilkins, 2008:32-87.

Eigenbrodt AK, Ashina H, Khan S, Mitsikostas DD, Sinclair AJ and Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501-14 Doi.10.1038/s41582-021-00509-5.

Lipton RB and Bigal ME. Migraine: epidemiology, impact and risk factors for progression. Headache. 2005;45(1):3-13 Doi.10.1111/j.1526-4610.2005.4501001.x.

Melhado EM, Santos PSF, Kaup AO, Costa ATNMD, Roesler CAP, Piovesan EJ, ... and Fragoso YD. Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic treatment of episodic migraine: Part I. Arq Neuropsiquiatr. 2022;80(8):845-61 Doi. 10.1055/s-0042-1756441.

Loder E, Burch R and Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930-45 Doi.10.1111/j.1526-4610.2012.02185.x.

Benemei S, De Logu F, Li Puma S, Marone IM, Coppi E, Ugolini F, … and Nassini R. The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel. Br J Pharmacol. 2017;174(17):2897-911 Doi.10.1111/bph.13917.

Kleeberg-Hartmann J, Vogler B and Messlinger K. Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels. J Headache Pain. 2021;22:23-25. Doi.10.1186/s10194-021-01235-5.

Thomet OAR, Wiesmann UN, Schapowal A, Bizer C and Simon HU. Role of petasin in the potencial anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol. 2001;61(8):1041-7 Doi.10.1016/S0006-2952(01)00552-4.

Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF and Ren J. Cellular calcium regulatory machinery of vasorelaxation elicited by petasina. Clin Exp Pharmacol Physiol. 2010;37(3):309-15 Doi.10.1111/j.1440-1681.2009.05283.x.

Grossmann M and Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther. 2000;38(9):430-5 Doi.10.5414/cpp38430.

Kulinowski L, Luca SV, Minceva M and Skalicka-Woźniak K. A review on the ethnobotany, phytochemistry, pharmacology and toxicology of butterbur species (Petasites L.). J Ethnopharmacol. 2022;293:115263 Doi.10.1016/j.jep.2022.115263.

Bickel D, Roder T, Bestmann HJ and Brune K. Identification and characterization of inhibitors of peptide-leukotriene-synthesis from Petasites hybridus. Planta Med. 1994;60(4):318-22 Doi.10.1055/s-2006-959492.

Fu PP, Yang YC, Xia Q, Chou MW, Cui YY and Lin G. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal. 2002;10(4):198-211.

Diener HC, Freitag FG and Danesch U. Safety profile of a special butterbur extract from Petasites hybridus in migraine prevention with emphasis on the liver. Cephalalgia. 2018;1(1):1-8 Doi.10.1177/251581631875930.

Prieto JM. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Botanics: Targets and Therapy. 2014;4:1-9 Doi.10.2147/BTAT.S54023.

Utterback G, Zacharias R, Timraz S and Mershman D. Butterbur extract: prophylactic treatment for childhood migraines. Complement Ther Clin Pract. 2014;20(1):61-4 Doi.10.1016/j.ctcp.2012.04.003.

Anderson N and Borlak J. Hepatobiliary events in migraine therapy with herbs-the case of Petadolex, A Petasites hybridus extract. J Clin Med. 2019;8(5):652 Doi.10.3390/jcm8050652.

Lipton RB, Göbel H, Einhäupl KM, Wilks K and Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63(12):2240-4 Doi.10.1212/01.wnl.0000147290.68260.11.

Borlak J, Diener HC, Kleeberg-Hartmann J, Messlinger K and Silberstein S. Petasites for migraine prevention: new data on mode of action, pharmacology and safety. A narrative review. Front Neurol. 2022;13:864689 Doi.10.3389/fneur.2022.864689.

Edvinsson L, Haanes KA and Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483-90 Doi.10.1038/s41582-019-0216-y.

Silva-Néto RP, Rodrigues ÂB, Cavalcante DC, Ferreira PH, Nasi EP, Sousa KM, ... and Valença MM. May headache triggered by odors be regarded as a differentiating factor between migraine and other primary headaches? Cephalalgia. 2017;37(1):20-8 Doi.10.1177/0333102416636098.

Diener HC, Rahlfs VW and Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51(2):89-97 Doi.10.1159/000076535.

Pothmann R and Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45(3):196-203 Doi.10.1111/j.1526-4610.2005.05044.x.

Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, … and Resch F. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain. 2008;12(3):301-13 Doi.10.1016/j.ejpain.2007.06.003.

Downloads

Published

2024-09-30

How to Cite

1.
Silva-Néto RP. Petasites hybridus in migraine prophylaxis: literature review. Headache Med [Internet]. 2024 Sep. 30 [cited 2024 Oct. 9];15(3). Available from: https://headachemedicine.com.br/index.php/hm/article/view/1311

Issue

Section

Review

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>